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Abstract
Background: Parity is well established as a risk factor for cervical cancer. It is not clear, however, how pregnancy
influences the natural history of HPV infection and cervical neoplasia. Our objective was to study the risk of HPV
infection and cervical squamous intraepithelial lesions (SIL) after pregnancy.
Methods: We used the Ludwig-McGill cohort study which includes 2462 women recruited in Sao Paulo, Brazil in
1993–97 and followed for up to 10 years. Cellular specimens were collected every 4–6 months for Pap cytology and
HPV detection and genotyping by a polymerase chain reaction protocol. Study nurses recorded pregnancy occurrence
during follow-up. HPV and Pap results from pregnant women were available before and after, but not during pregnancy.
The associations between pregnancy and post-partum HPV infection/SIL were studied using generalized estimating
equation models with logistic link. Adjusted odds ratios (OR) were estimated with empirical adjustment for confounding.
Results: We recorded 122 women with a history of pregnancy during follow-up. Of these, 29 reintegrated the cohort
study after delivery. No association between HPV and pregnancy was found. A single SIL case (high grade SIL) occurred
post-partum. Likewise, there was no association between pregnancy and risk of low grade SIL or any-grade SIL at the
next visit (adjusted OR = 0.84, 95 % CI: 0.46-15.33) after controlling for confounders.
Conclusions: No associations were found between pregnancy and HPV or LSIL. The single observed case of HSIL
post-partum was more than would be expected based on the rate of these abnormalities among non-pregnant
women. As this association was found with only one case, caution is required in the interpretation of these results.
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Background
The central causal role of the so-called high oncogenic–
risk (HR)-human papillomavirus (HPV) genotypes, such
as HPV-16 in cervical carcinogenesis, has been estab-
lished [1]. HPV is a necessary but not sufficient cause of
virtually all cases of cervical cancer worldwide. HR-HPV
infection also causes a substantial proportion of other
anogenital neoplasms and oral squamous cell carcinomas
[2]. HPV infections are one of the most common sexually
transmitted conditions in the world although the vast ma-
jority are transient, with only a small proportion becoming
persistent and leading the development of cervical cancer
[3]. The fact that HPV infection does not always progress
to neoplastic disease suggests that interpersonal variations
in the immune system may play a role in the clearance of
HPV infections and/or in their acquisition. Other viral or
environmental factors may also play a role [4]. For ex-
ample, parity is a well-established risk factor for cervical
cancer [5]. It is not clear, however, exactly how pregnancy
influences the natural history of human papillomavirus
(HPV) infection and cervical neoplasia. To our knowledge,
there is no prospective study of the risk conferred by preg-
nancy on both HPV infection and cervical intraepithelial
neoplasia. The aim of this prospective study was to analyse
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the risk of HPV infection and cervical squamous intrae-
pithelial lesion following pregnancy.
Method
Subject recruitment
The women included in this study were enrolled into the
Ludwig-McGill cohort, a longitudinal investigation of the
natural history of HPV infection and precursor lesions of
cervical cancer. A detailed description of the design and
methods of the study has been published previously [6].
Briefly, women attending a maternal and child health pro-
gram catering to a low-income neighborhood in São Paulo
(Brazil) were recruited between 1993 and 1997 and
followed for up to 10 years. Women were eligible to partici-
pate if they: 1) were between 18 and 60 years of age, 2) were
permanent residents of São Paulo, 3) were not currently
pregnant and had no intention of becoming pregnant dur-
ing the first year of follow-up, 4) had an intact uterus and
no current referral for hysterectomy, 5) reported no use of
vaginal medication in the previous 2 days and 6) had no re-
ported treatment for cervical disease in the previous
6 months. Subjects gave a signed informed consent. The
study protocol was approved by institutional ethical and re-
search review boards of the participating institutions in
Canada (McGill University Research and Ethics Board,
Montreal) and in Brazil (Ludwig Institute for Cancer
Research São Paulo Branch Institutional Review Board
(IRB) and by the IRB of the Hospital e Maternidade Escola
Vila Nova Cachoerinha Dr Mario Altenfender, São Paulo).
The study enrolled 2528 women, corresponding to a
70 % response rate and subsequently, 66 ineligible women
were excluded. Follow-up for the remaining 2462 women
consisted of 1 visit every 4 months for the first year and 2
visits per year thereafter. Cervical specimens were taken
for Papanicolaou (Pap) cytology and HPV testing at every
visit with a fixed-sampling area Accelon device. For the
first 4 visits and for each annual visit thereafter, subjects
answered a nurse-administered questionnaire designed to
collect information on socio-demographic, lifestyle, sexual,
reproductive and contraceptive characteristics. Pregnancy
status was registered by study nurses along with date and
procedures of visits, reasons of dropouts and reintegra-
tion, and other study-relevant incidents. Pregnant women
were excluded from the study during pregnancy and of-
fered to be reintegrated in the study after a minimum of
45 days following delivery, if there was no clinical impedi-
ment and if they consented. HPV and Pap results from
pregnant women were available before and after, but not
during pregnancy.
Cervical cells specimen
An Accelon biosampler (Medscand, Inc., Hollywood,
Florida) was used to collect ecto- and endocervical sam-
ples for each visit and a Pap smear was prepared on a
glass slide and fixed with 95 % ethanol. The sampler
containing the residual exfoliated cells was immersed in
a tube containing Tris-EDTA buffer (pH 7.4) and agi-
tated to release the cells. The tubes containing cell sus-
pensions were frozen until testing. Samples were then
sent to the Ludwig Institute for storage and testing. Pap
smears were sent to the study centre in Canada for cy-
tology reading by one of the co-authors (AF). Cytopa-
thology reports were based on the 1991 Bethesda
system for cytological diagnoses [7]; the Pap smears
were read ‘blinded’ to all other test results for the
same sample and for the same woman and findings
were classified as normal, atypical squamous cells of
undetermined significance (ASCUS), atypical glandu-
lar cells of undetermined significance (AGUS), low
grade squamous intraepithelial lesion (LSIL), or high
grade squamous intraepithelial lesion (HSIL).
HPV DNA testing
The Accelon device containing ecto- and endocervical
cells was placed in a tube containing Tris-EDTA buffer
(pH 7.4). DNA was extracted, purified by spin column
chromatography, and amplified by polymerase chain re-
action (PCR), using the MY09/11 and PGMY protocols
[8, 9] for detection of HPV DNA. Typing of amplified
products was performed by dot-blot hybridization with
individual oligonucleotide probes and by restriction
fragment length polymorphism (RFLP) analysis. This
method identified more than 40 HPV genital types.
Amplified products that hybridized only with a generic
probe and were unidentifiable in RFLP analysis were
classified as positive for unknown types. The genotypes
tested included high oncogenic risk (HR-) HPV types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73
and 82, and low oncogenic risk (LR-) HPV types 6, 11,
26, 32, 34, 40, 42, 44, 53, 54, 57, 61, 62, 67, 69, 70, 71,
72, 81, 83, 84 and 89 (unknown types considered LR-
HPVs) [10, 11]. We included more than 30 type-
specific positive controls in hybridization membranes
to control for experimental variation between different
membranes. DNA specimen quality was checked by
amplification of a 268-bp human β–globin gene region
[8]. Specimens were tested blindly and precautions
were taken to prevent contamination. Samples that
were negative for both HPV and β–globin were consid-
ered inadequate for analysis.
Statistical analysis
We explored the relationships between pregnancy and
outcomes such as HPV infection and cervical squamous
intraepithelial lesions (SIL) using generalized estimating
equation (GEE) via a logistic regression link, which take
into account the clustering within each individual caused
by the repeated-measurements design. GEE models were
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based on an exchangeable correlation pattern. We
studied the association between pregnancy and the
presence of HPV, LSIL and HSIL. Post-partum visits
were compared to other usual visits for the presence
of HPV or SIL. We explored the relationship between
HPV infection and pregnancy by considering grouped
HPV genotypes per their oncogenic potential (high-risk
and low-risk as described above), per their phylogenetic
relationship within the genus Alpha-papillomavirus (spe-
cies 3, 5, 6, 7, 9, 10) [12] and grouped HPV per their gen-
eral tropism for the cervix or the vagina [13]. HPV group
1 (benign) included HPV types 6, 11, 32, 40, 42, 44 (cer-
vical and vaginal species 1, 8, 10); HPV group 2 included
HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 67, 68, 69, 70, 82 (cervical species 5, 6, 7, 9, 11);
and HPV group 3 included HPV types 57, 61, 71, 72, 62,
81, 83, 84, 89 (vaginal species 3, 4, 15).
We estimated crude and adjusted odd ratios (ORs) with
respective 95 % confidence intervals (CI). For adjusted esti-
mates, we controlled for empirical confounders using a 5 %
change-in-estimate method (variables that changed the esti-
mates by +/− 5 % were included in the model) considering
the following variables: age at enrolment (linear), race
(white, non-white), marital status (single, married, widowed,
separated, unmarried but living with partner), income
(quartiles of income), smoking (never, current, former), age
at first sexual intercourse (≤15, 16–17, 18–19, 20+), num-
ber of previous pregnancies (0–1, 2–3, 4–6, 7+), Pap testing
before enrollment in the cohort (yes, no) and lifetime num-
ber of sexual partners (0–1, 2–3, 4+). For the analysis con-
cerning the association between SIL and pregnancy, we
also considered HPV status (negative, LR-HPV only, any
HR-HPV) as a potential confounder or mediator.
Results
A total of 2475 women were included and provided
altogether 24,558 visits. The mean and median follow-up
time were 5.1 (SD = 3.2 years) and 6.4 (inter-quartile
range = 1.0-7.5) years, respectively. The mean age at en-
rolment was 32.7 years (SD = 8.8; median = 32, range:
18–59) and most women were white (64 %). We re-
corded 122 women with a history of pregnancy during
follow-up. After giving birth, 29 (23.8 %) women reen-
tered the study. The mean time between visits for reinte-
gration into the cohort was 3.9 years (SD = 1.6).
Table 1 describes the characteristics at baseline (enrol-
ment) according to the pregnancy status in the course of
follow-up. Women who became pregnant over the
course of follow-up were younger than those in the re-
mainder of the cohort. The distribution of other age-
dependent variables also differed according to pregnancy
outcomes, e.g., women who did not become pregnant
were more likely to have a normal cytology result and to
be HPV negative at baseline. Table 1 also provides
baseline data for women who had a pregnancy but who
did not reintegrated the cohort after pregnancy. Overall,
women lost to follow-up after pregnancies were largely
comparable to those who reintegrated into the cohort
after giving birth.
Table 2 presents the crude and adjusted ORs for the as-
sociation between pregnancy and post-partum HPV infec-
tion and SILs. Six of the post-pregnancy visits were HPV
positive (20.7 %), whereas 3787 out of 23,735 (16.0 %)
visits without an intervening pregnancy yielded the same
finding. We found no evidence that pregnancy increased
the risk of detecting HPV at the next visit post-partum ir-
respective of the categories used to group HPV genotypes
(range of adjusted ORs: 0.80-1.86; none statistically signifi-
cant). Table 2 also shows the association between preg-
nancy and cytological abnormalities. A single SIL case (an
HSIL) occurred post-partum. Likewise, there was no asso-
ciation between pregnancy and LSIL or any-grade SIL at
the next visit (adjusted OR = 0.84, 95 % CI: 0.46-15.33)
after controlling for confounders. The single observed
case of HSIL post-partum was more than would be ex-
pected based on the rate of these abnormalities among
non-pregnant women even after accounting for multiple
confounders (OR = 8.75, 95 % CI: 1.00-77.03).
Discussion
In this longitudinal study, we analysed the risk of HPV
infection and cytological abnormality following preg-
nancy. No association was detected between pregnancy
and LSIL, nor for post-partum HPV infection. Although,
the single observed case of HSIL post-partum was more
than would be expected based on the rate of these ab-
normalities among non-pregnant women, this associ-
ation was found with only one case, which calls for
caution in interpreting these findings.
There are plausible mechanisms whereby pregnancy
may influence the natural history of HPV infection and
progression to clinical lesions. Increased levels of estro-
gen or growth hormone associated with pregnancy such
as human chorionic gonadotropin (hCG) may increase
HPV molecular activity [14, 15]. Studies on condyloma
acuminata and laryngeal recurrent respiratory papillo-
matosis have shown that these lesions increase in num-
ber and size during pregnancy [16]. Others suggested
that a reduced humoral response to HPV may occur in
pregnant women [17].
Our finding of no increased risk of HPV detection
with pregnancy concurs with other reports [18–27].
Only a few showed a higher risk of HPV infection in
pregnant women [28–30]. The higher risk of HPV infec-
tion in these studies could be explained by confounding
variables related to sexual activity, as pregnancy and
HPV infection are both acquired through sex. Some
studies have shown a higher risk of HSIL with
Trottier et al. BMC Pregnancy and Childbirth  (2015) 15:244 Page 3 of 7
pregnancy. Morimura et al. (2002) [31] have shown that
the proportion of women with of abnormal Pap test re-
sults was significantly higher during pregnancy. Jensen
and colleagues (2013) [32] found that childbirth in-
creased the risk of HSIL, over and above the risk of
persistent HPV infection. Taken together, those studies
Table 1 Characteristics at baseline (at enrolment in the cohort) according to pregnancy status in the course of follow-up
Characteristics at baseline Women without pregnancy




Pregnant women who did not
reintegrate the cohort following
pregnancy
*p-value
N = 2353 N = 29 N = 93
Age (mean, SD) 32.7 (8.8) 26.7 (6.1) 27.2 (5.4) 0.609
Age (median, IQR) 32.0 (26.0-39.0) 26.0 (21.0-31.5) 27.0 (22.3-31.0)
(%) (%) (%)
Cytology Negative 96.2 86.2 90.0
ASC/AGUS 1.7 0.0 5.0 0.221
LSIL 1.2 6.9 1.3
HSIL 0.7 6.9 3.8
HPV status Neg 82.6 72.4 77.5
LR-HPV only 6.4 10.3 5.0 0.600
Any-HR 10.1 17.2 16.3
Ethnicity White 64.9 55.2 53.8
Nonwhite 35.1 44.8 46.3 0.895
Marital status Single 10.3 6.9 10.0 0.148




Widowed/Separated 8.3 3.5 1.3
Quartiles of income 1 (lowest) 24.8 37.9 27.9
2 24.8 17.2 25.3 0.069
3 25.3 34.5 17.7
4 (highest) 25.1 10.3 29.1
Age at first intercourse 20+ 26.4 13.8 12.5
18-19 21.2 0.0 25.0 0.324
16-17 25.6 37.9 26.3
<=15 26.9 48.3 36.3
Previous pregnancy 0-1 16.9 24.1 20.0
2–3 42.8 24.1 42.5
4–6 30.1 44.8 27.5 0.231
7+ 10.2 6.9 10.0
Lifetime number of
sexual partners
0-1 44.3 44.8 41.3
2-3 34.7 31.0 40.0
4+ 20.9 24.1 18.8 0.662
Ever had PAP
cytology before
No 5.0 3.5 12.5
Yes 95.0 96.6 87.5 0.166
Smoking Never 47.6 51.7 40.0
Current 34.9 27.6 43.8 0.312
Former 17.4 20.7 16.3
*P-value to test the difference between pregnant women who reintegrated and those who did not reintegrate the cohort following pregnancy. P-values estimated
with Pearson's chi-squared for categorical variables and student t-test for continuous variables
Total may not sum 100 % due to missing data. SD standard deviation, IQR interquartile range
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suggest, that careful monitoring of HPV positive
women in the post-partum period may be warranted.
It is not clear however, whether or not the risk of pro-
gression of HPV infection to cervical neoplasia (preinvasive
and invasive cancer) is higher when detected during preg-
nancy. Studies on the progression of biopsy proven cervical
neoplasia during pregnancy are rare, since biopsies tend to
be avoided during pregnancy. When Pap results are used to
estimate risk, reports provide a wide range of estimates:
10–70 % of cytological abnormalities found during preg-
nancy regress, 25–89 % persist without progression and 3–
30 % progress [33–46]. Studies on evolution of HSIL during
pregnancy and the post-partum period show a range of
progression to micro-invasive carcinoma from 0 to 14.2 %
and a very low risk of progression to frankly invasive cancer
(0.1 %) (reviewed in Serati et al., [44]).
This study has limitations. It is possible that residual
confounding may explain our findings. For example, lack
of control for women’s partners’ sexual behaviour could
create confounding if pregnancy is associated with a
higher likelihood of partners’ extra-conjugal sexual rela-
tionships. However, this potential confounding bias is un-
likely to have occurred, as no association was found for
HPV infection or LSIL. We also used cytology and not
histology results in this analysis. However, Morimura et al.
(2002) [31] has shown that the accuracy of cytology Pap
testing is similar between pregnant and non-pregnant
women. As this potential information bias is non differen-
tial, it would have only underestimated the relative risk we
found. Finally, most of the women in our cohort
already had their children at the time of recruitment
and only a small number of women experienced a preg-
nancy within the cohort. Moreover, a criterion for re-
cruitment in our cohort was not being currently
pregnant and no intention of becoming pregnant dur-
ing the first year of follow-up, which reduced the num-
ber of pregnancies in the cohort and the number of
women who reentered the cohort after birth.
Table 2 Crude and adjusted odds ratios (ORs) for the association between HPV detection or squamous intraepithelial lesion (SIL)
and pregnancy
Outcome Post pregnancies observation visits (n) Crude OR 95 % CI Adjusted ORc 95 % CI
No pregnancy Pregnancy
HPVb aHPV (−/+) aHPV (−/+)
Any HPV 19948/3787 23/6 0.85 (0.33–2.14) 0.80 (0.31–2.07)
Any HR-HPV 19948/2281 23/3 0.80 (0.24–2.65) 0.80 (0.24–2.71)
LR-HPV only 19948/1506 23/3 1.15 (0.31–4.23) 1.18 (0.34–4.15)
Speciesb
3 19948/638 23/1 1.49 (0.26–8.50) 1.32 (0.22–7.97)
5 19948/343 23/1 2.32 (0.35–15.23) 1.86 (0.28–12.15)
6 19948/505 23/1 1.06 (0.11–9.83) 0.91 (0.10–8.12)
7 19948/645 23/1 1.23 (0.20–7.60) 0.98 (0.15–6.24)
9 19948/1407 23/1 0.48 (0.07–3.21) 0.43 (0.07–2.59)
10 19948/303 23/1 1.26 (0.09–17.40) 1.29 (0.13–12.93)
Group
1 (species-1/8/10/13) 19948/399 23/1 0.93 (0.64–13.53) 1.05 (0.10–10.53)
2 (species-5/6/7/9/11) 19948/2566 23/4 0.87 (0.29–2.56) 0.77 (0.27–2.21)
3 (species-2/3/4/15) 19948/716 23/1 1.41 (0.26–7.64) 1.25 (0.21–7.29)
Squamous intraepithelial lesions (SILs) SIL (−/+) SIL (−/+)
Low-grade SILs 23845/258 28/0 – – – –
High-grade SILs 23845/76 28/1 7.77 (0.93–65.08) 8.75 (1.00–77.03)
Any-grade SILs 23845/334 28/1 0.91 (0.05–18.27) 0.84 (0.46–15.33)
aExcludes women-visits for which HPV testing was invalid or missing
bSee text for definition of grouped HPV genotypes
cAdjustment for empirical confounders was done using a 5 % Change-in-Estimate Method (variables that changed the estimates by +/− 5 % were included in the
model) considering the following variables as a potential confounder: age at enrolment (linear), race (white, non-White), marital status (single, married, widowed,
separated, unmarried but living with partner), income (quartiles of income), smoking (never, current, former), age at first sexual intercourse (≤15, 16–17, 18–19, 20
+), number of previous pregnancies (0–1, 2–3, 4–6, 7+), Pap testing before enrollment in the cohort (yes, no), and lifetime number of sexual partners (0–1, 2–3, 4
+). Adjustment for HPV status (negative, LR-HPV only, any HR-HPV) was considered for the analysis of SILs. Confounding variables added to the multivariate
models for HPVs (variables that changed the OR for the relation between pregnancy and HPV status by +/− 5 %) were: number of previous pregnancies, age at
first sexual intercourse, age, race and smoking status. For SILs, confounding variables added to the multivariate models were: HPV status, age, smoking, race, age
at first sexual intercourse, number of previous pregnancies and Pap testing before entering the cohort
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One of the strengths of our study was the use of a lon-
gitudinal design approach including prospective collec-
tion of data before and after pregnancy. This limits the
potential for bias that would have occurred if pregnant
women were more likely to be screened compared to
non-pregnant women because all pregnant women in
our study were similarly followed-up in the cohort prior
to becoming pregnant. We also applied a conservative
control for confounding including sexual behaviour and
variables that were different between pregnant and non
pregnant women such as age.
Conclusions
In conclusion, we found no association between preg-
nancy and HPV infection and cervical lesions but admit-
tedly, our cohort included a limited number of pregnant
women. A single SIL case (an HSIL) occurred post-
partum which calls for caution in interpretation.
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